

ASX Announcement 8 July 2016

ITL Wins Additional SSK Contract Extension

ITL Limited, the diversified healthcare company and owner of MyHealthTest, the provider of direct to consumer pathology testing, is pleased to announce a contract extension of 14 months with a large US community blood bank for its SampLok Sampling Kit ("SSK").

ITL BioMedical, a division of ITL has been a supplier to this blood center for over three years. SSK is used in the global blood banking market to transfer platelet samples when performing bacterial detection testing.

This contract extension is in line with ITL's previously stated strategy to maintain strong sales of SSK in the US whilst reaching new markets. In 2016 SSK has also been accepted by OneBlood, a major US blood bank, and been granted patent protection by the US Patents and Trademarks Office and regulatory approval by both the US FDA and Taiwan FDA (where it also won its maiden contract).

Bill Mobbs, Executive Chairman commented "this contract extension with one of the largest US community-based blood collection organizations in the US is a very good achievement for ITL BioMedical."

"We are very pleased with the growth in sales and acceptance of SSK that are paving the way for further successes through the year."

Bill Mobbs
Executive Chairman

About ITL BioMedical

ITL BioMedical is a division of ITL Limited. The division has a range of bacterial screening ancillaries as part of its wider portfolio of biological sampling and transfer kits. The division's products are distributed by industry leaders and partners around the world.

Please note this announcement corrects statement made 7 July 2016 that said patent approval was given by US and Taiwan FDA bodies but which should have said regulatory approvals approvals were given.

ITL Limited ABN 16 088 212 088 Unit 1, 63 Wells Road Chelsea Heights, Victoria, 3196

ITL is an innovative diversified medical technology company that creates and manufactures leading edge medical devices for Operating Theatres, Bloodbanks and laboratories.

ITL's patented medical devices are sold in over 50 countries and protect healthcare workers in millions of procedures annually.

ITL's wholly owned subsidiary MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.

Australian Securities Exchange

Code: ITD

Ordinary Shares

Board of Directors

95,,357,346

Bill Mobbs Executive Chairman

Mark Peatey Non-executive Director
Andrew Turnbull Non-executive Director

Trevor Doolan Chief Financial Officer &

Company Secretary

ITL Contact

Trevor Doolan Company Secretary
Phone: +61 3 8773 3050
Email: info@itl-limited.com

www.itl-limited.com

Media

Ben Knowles Walbrook IR
Phone: +61 426 277 760
Email: ben.knowles@walbrookir.com.au